Rahul R Deshmukh, M.S., Ph.D.

Associate Professor
Glendale, AZ

Home / Academics / Our Faculty / Rahul R Deshmukh, M.S., Ph.D.


Dr. Rahul Deshmukh received his Bachelor of Pharmacy degree from University of Pune and Master of Pharmacy degree from Bharati Vidyapeeth University, India. He also received his Master of Science in Pharmaceutical Sciences degree from University of Maryland, Baltimore. He completed his Ph.D. from Wayne State University (WSU). His research during Ph.D. was focused on the study of crosstalk between 5’-AMP-activated Protein Kinase (AMPK) and Ubiquitin Proteasome System (UPS) as well as novel ways to sensitize solid tumors to proteasome inhibitors.

With more than 15 years of research experience, his research focuses on ‘Drug design and discovery’, ‘Novel drug delivery systems’, ‘Natural products’, ‘Repurposing FDA approved drugs’ and 'Immunotherapy'. Dr. Deshmukh has contributed to many publications so far including original research, review articles and a book chapter. Currently, he serves on the editorial board and as an ad hoc reviewer for several peer reviewed scientific journals.

Associate Professor

Glendale, AZ

College of Pharmacy
Glendale Campus

Pharmaceutical Sciences


Call My


Send Me
a Message



Wayne State University | 0 | Ph.D.

Courses Taught

Pharmacology, Medicinal Chemistry, Pathophysiology, Pharmacogenomics, Clinical Toxicology, Biotherapeutics


  1. Immunotherapies and Combination Strategies for Immuno-Oncology, Cody Barbari, Tyler Fontaine, Priyanka Parajuli, Narottam Lamichhane, Silvia Jakubski, Purushottam Lamichhane, Rahul R. Deshmukh, Int. J. Mol. Sci., 2020, 21(14), 5009
  2. The war against tuberculosis: A review of natural compounds and their derivatives, Morgan Maiolini, Stacey Gause, Jerika Taylor, Tara Steakin, Ginger Shipp, Purushottam Lamichhane, Bhushan Deshmukh, Vaibhav Shinde, Anupam Bishayee and Rahul R. Deshmukh, Molecules, 2020, 25(13), 3011
  3. Colorectal Cancer and Probiotics: Are bugs really drugs?, Purushottam Lamichhane, Morgan Maiolini, Omar Alnafoosi, Sedra Hussein, Hasan Alnafoosi, Stewart Umbela, Tayanna Richardson, Nevien Alla, Narottam Lamichhane, Bobban Subhadra and Rahul R. Deshmukh, Cancers, 2020, 12(5), 1162
  4. Resistance to Checkpoint Inhibition in Cancer Immunotherapy, Luisa Barrueto, Francheska Caminero, Lindsay Cash, Courtney Makris, Purushottam Lamichhane, Rahul R. Deshmukh, Translational Oncology, Volume 13, Issue 3, March 2020, 100738
  5. Novel Delivery Systems for Checkpoint Inhibitors, Purushottam Lamichhane, Rahul Deshmukh, Julie A. Brown, Silvia Jakubski, Priyanka Parajuli, Todd Nolan, Dewan Raja, Mary Badawy, Thomas Yoon, Mark Zmiyiwsky, Narottam Lamichhane, Medicines, 2019, 6(3), 74
  6. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer, Stewart Umbela, Shahinaz Ghacha, Revika Matuknauth, Stacey Gause, Shrijana Joshee, Rahul R. Deshmukh, Current Problems in Cancer, May, 2019
  7. Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma, Stephanie Wills, Lana K Hochmuth, Kenneth S Bauer Jr, Rahul Deshmukh, Current Problems in Cancer, Volume 43, Issue 3, June 2019, Pages 181-194
  8. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells, Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM, Nutrients. 2018 Nov; 10(11): 1644
  9. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma, Amanda Teets, Linda Pham, Thi Tran, Lana Hochmuth, Rahul R. Deshmukh, Critical Reviews in Immunology, Volume 38, Issue 3, 2018, pages 159-206
  10. Pentacyclic triterpenes: New tools to fight metabolic syndrome, Hitender Sharma, Pushpander Kumar, Rahul R. Deshmukh, Sunil Kumar, Phytomedicine, Volume 50, 15 November 2018, Pages 166-177
  11. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors, Deshmukh RR, Kim S, Elghoul Y, Dou QP, J Cell Biochem. Nov 2016
  12. PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery, Luong D, Kesharwani P, Deshmukh R, et al, Acta Biomater. 2016 Oct 1;43:14-29
  13. Deubiquitinases (DUBs) and DUB inhibitors: a patent review, Pershang Farshi, Rahul R Deshmukh, Joseph O Nwankwo, Richard T, Arkwright, Boris Cvek, Jinbao Liu & Q Ping Dou, Expert Opin. Ther. Patents (2015) 25(10):1191-1208
  14. Proteasome inhibitors induce AMPK activation via CAMKKβ in human breast cancer cells, Rahul R. Deshmukh, Dou QP, Breast Cancer Res Treat (2015) 153:79-88
  15. TNF-α sensitize breast cancer cells to natural products with proteasome inhibitory activities leading to   apoptosis, Li Lu, Wenli Shi, Rahul R. Deshmukh et al, PLOS ONE, Nov, 2014
  16. L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells, Zhongyu Zhang, Caifeng Bi, Yuhua Fan, Nan Zhang, Rahul Deshmukh et al,  Journal of Biological Inorganic Chemistry, Dec 03, 2014
  17. Lessons from Nature: Development of Novel AMPK Activators for Cancer Treatment, Richard Arkwright, Rahul Deshmukh et al, Anti-Cancer agents in Medicinal Chemistry, Dec 14, 2014
  18. Mechanisms of action and resistance to proteasome inhibitors in human cancer, Schmitt S, Rahul R. Deshmukh, Dou QP, Resistance to targeted anticancer therapeutics  Springer, 2014, pages 1-46 (book chapter)
  19. Chemotherapeutic inhibitors in the treatment of prostate cancer, Rahul R. Deshmukh, Schmitt S, Dou QP, Expert Opinion in Pharmacotherapy, Volume 15, No.1, 2014, pages 11-22
  20. From Bortezomib to other Inhibitors of the Proteasome and Beyond, Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R et al, Curr Pharm Des. 2013; 19(22):4025-38
  21. Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and Caspase-9, Sarice R. Boston, Rahul Deshmukh et al, BMC Cancer; 2011, 11:7
  22. Development of extracellular signal regulated kinase inhibitors, Kimberly Burkhard, Sarice Smith, Rahul Deshmukh et al, Curr Top Med Chem. 2009;9(8):678-89
  23. Hypoglycemic activity of roots of Phyllanthus reticulates in alloxan induced diabetic mice, S. Kumar, D. Kumar, R. R. Deshmukh and V. D. Rangari, Internat. J. of Plant Sci, Volume 2, no.1, Jan, 2007, 184-187


American Association of Pharmaceutical Scientists

American Association of Colleges of Pharmacy